NextCure to Present at the 40th Annual Cowen Health Care Conference
February 25 2020 - 8:05AM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced that it will present at
the 40th Annual Cowen Health Care Conference in Boston on March 4
at 8:00 am.
A live audio webcast will be available through
the Investors section of the company’s website at www.nextcure.com.
A replay of the webcast will be available approximately two hours
after the event and archived on the website for 30 days.
About NextCure, Inc.NextCure is
a clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in order to develop immunomedicines. Our
initial focus is to bring hope and new treatments to patients who
do not respond to current cancer therapies, patients whose cancer
progresses despite treatment and patients with cancer types not
adequately addressed by available therapies.
http://www.nextcure.com
Cautionary Statement Regarding
Forward-Looking Statements Statements made in this press
release that are not historical facts are forward-looking
statements. Words such as “expects,” “believes,” “intends,” “hope,”
“forward” and similar expressions are intended to identify
forward-looking statements. Examples of forward-looking statements
in this press release include, among others, statements about
NextCure’s plans, objectives and intentions with respect to the
discovery of immunomedicine targets and the discovery and
development of immunomedicines. Forward-looking statements involve
substantial risks and uncertainties that could cause actual results
to differ materially from those projected in any forward-looking
statement. Such risks and uncertainties include, among others: our
limited operating history and no products approved for commercial
sale; our history of significant losses; our need to obtain
additional financing; risks related to clinical development,
marketing approval and commercialization; and the unproven approach
to the discovery and development of product candidates based on our
FIND-IO platform. More detailed information on these and additional
factors that could affect NextCure’s actual results are described
in NextCure’s filings with the Securities and Exchange
Commission (the “SEC”), including in the Risk Factors section
and throughout NextCure’s Form 10-Q filed with
the SEC on November 12, 2019. You should not place
undue reliance on any forward-looking statements. NextCure assumes
no obligation to update any forward-looking statements, even if
expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Apr 2023 to Apr 2024